No statistical significance ,between the two arms, regarding the OVERALL survival in this RCT funded by the supplier and manufacturer of the immunotherapy in question….
You are here:
Neoadjuvant Nivolumab plus Chemotherapy in Resectable Lung Cancer
Submitted by: Aristotle Protopapas
Source: The New England Journal of Medicine
Keywords:
Author(s): the CheckMate 816 Investigators
